Physician profile
Ashish Chawla
NPI 1750346730
$49,647.98
in general payments reported to CMS, 2019-2025
21 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $125 · 2021: $11K · 2022: $7,569 · 2023: $14K · 2024: $15K · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $5,550 · Travel and Lodging: $3,406 · Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,512.50 |
| Consulting Fee | $5,550.00 |
| Travel and Lodging | $3,405.81 |
| Food and Beverage | $1,054.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $48,379.31 | 2021-2025 | Microstream, Capnostream20p |
| Abbvie INC. | $208.37 | 2019-2023 | Rinvoq |
| Shire North American Group INC | $200.00 | 2019 | |
| Pfizer INC. | $161.84 | 2019-2020 | |
| Janssen Biotech, INC. | $135.94 | 2019-2023 | Simponi Aria, Remicade, Stelara |
| Celgene Corporation | $123.97 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.60 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $43.53 | 2019-2020 | |
| Boston Scientific Corporation | $40.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.71 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $28.00 | 2019 | |
| Allergan, INC. | $24.19 | 2019 | |
| Merck Sharp & Dohme LLC | $23.36 | 2025 | Bridion |
| Genzyme Corporation | $22.19 | 2024 | |
| Qol Medical, LLC | $19.82 | 2023 | Sucraid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.27 | 2023 | |
| Alfasigma USA, INC. | $17.07 | 2020 | |
| Shionogi INC | $16.01 | 2019 | |
| Vivus LLC | $15.98 | 2019-2020 | |
| Intra-Sana Laboratories | $14.08 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ironwood Pharmaceuticals, INC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.